Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing novel vaccines. The Company's products include HEPLISAV-B and CpG 1018TM. The HEPLISAV-B is for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The Company also manufactures and sells CpG 1018TM, the adjuvant used in HEPLISAV-B. The Company also engaged in developing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.